"VANQUISH" Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)
"NOVIS" Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will complete recruitment in 2023
ROCKAWAY, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.
The nVNS research presented at the 2023 World Stroke Congress covers two recently...